 |
Regeneron Reports Full Year and Fourth Quarter 2009 Financial and Operating Results
Feb 18, 2010
|
29.3 KB |
|
| |
TARRYTOWN, N.Y., Feb 18, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the full year and fourth quarter of 2009. The Company reported a net loss of $67.8 million, or $0.85 per share (basic and diluted), for the year ended December 31, 2009 compared w...
|
|
VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema
Feb 18, 2010
|
18.5 KB |
|
| |
TARRYTOWN, N.Y. and LEVERKUSEN, Germany, Feb 18, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME). The primary endpoint of the study, a statistically signifi...
|
|
Regeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference
Jan 7, 2010
|
7.9 KB |
|
| |
TARRYTOWN, N.Y., Jan 07, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2010. The presentation is scheduled for 1:00 p.m. Eastern Time. The session may be accessed through the Company's web sit...
|
|
Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
Dec 10, 2009
|
8.0 KB |
|
| |
TARRYTOWN, N.Y., Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Deutsche Bank 2009 Biotech Boston Confab on Tuesday, December 15, 2009. The presentation is scheduled for 3:35 p.m. Eastern Time. The session may be accessed through the Company's web ...
|
|
Regeneron Announces Presentation at the 21st Annual Piper Jaffray Healthcare Conference
Nov 24, 2009
|
8.0 KB |
|
| |
TARRYTOWN, N.Y., Nov 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 21st Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009. The presentation is scheduled for 4:00 p.m. Eastern Time. The session may be accessed through the Company'...
|
|
Regeneron Announces Conference Call to Discuss Expanded Antibody Collaboration with Sanofi-aventis
Nov 10, 2009
|
9.0 KB |
|
| |
TARRYTOWN, N.Y., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will host a conference call and live webcast at 8:30 a.m. Eastern Time on Wednesday, November 11 to discuss the company's expanded strategic antibody collaboration with sanofi-aventis, which was announced today.
Conf...
|
|
Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
Nov 10, 2009
|
14.5 KB |
|
| |
PARIS, and TARRYTOWN, N.Y., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human...
|
|
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Nov 3, 2009
|
27.5 KB |
|
| |
TARRYTOWN, N.Y., Nov 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN)today announced financial and operating results for the third quarter of 2009. The Company reported a net loss of $1.0 million, or $0.01 per share (basic and diluted), for the third quarter of 2009 compared with a net loss ...
|
|
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Oct 27, 2009
|
15.0 KB |
|
| |
TARRYTOWN, N.Y., Oct 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced it has received marketing authorization in the European Union for rilonacept, an interleukin-1 blocker, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including Fam...
|
|
Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
Oct 27, 2009
|
8.2 KB |
|
| |
TARRYTOWN, N.Y., Oct 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2009. The presentation is scheduled for 1:30 p.m. Eastern Time. The session may be accessed through the Compan...
|
|
Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
Oct 6, 2009
|
13.3 KB |
|
| |
TARRYTOWN, N.Y., Oct 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- State, county and local government leaders today joined senior management from Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and BioMed Realty Trust, Inc. (NYSE: BMR) to celebrate the completion of Regeneron's new 229,000 square foot corporate headquarters and research...
|
|
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Sep 14, 2009
|
13.9 KB |
|
| |
TARRYTOWN, N.Y., Sept 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD)...
|
|
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
Sep 11, 2009
|
14.2 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Sept 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line...
|
|
Regeneron Announces September 2009 Investment Conference Presentations
Sep 10, 2009
|
8.5 KB |
|
| |
TARRYTOWN, N.Y., Sept 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations that are scheduled for delivery later this month at the following investment conferences:
-- The Morgan Stanley Global Healthcare Unplugged Conference at 8:00 a.m.
Eas...
|
|
Regeneron Announces Presentation at the 29th Annual Canaccord Adams Global Growth Conference
Aug 7, 2009
|
8.8 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 7, 2009--
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its
presentation at the 29th Annual Canaccord Adams Global Growth
Conference on ...
|
|
Regeneron Reports Second Quarter 2009 Financial and Operating Results
Aug 4, 2009
|
75.0 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 4, 2009--
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced
financial and operating results for the second quarter of 2009. The
Company reported a net l...
|
|
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Jul 24, 2009
|
16.9 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jul. 24, 2009--
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the
Committee for Medicinal Products for Human Use (CHMP) of the European
Medi...
|
|
First Patient Enrolled in Regeneron and Bayer HealthCare VEGF Trap-Eye Phase 3 Program in Central Retinal Vein Occlusion
Jul 23, 2009
|
13.5 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jul. 23, 2009--
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced
that the first patient has been enrolled in the Phase 3 program of VEGF
Trap-Eye for the tre...
|
|
Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
Jun 11, 2009
|
20.4 KB |
|
| |
PARIS & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jun. 11, 2009--
Sanofi-aventis (Euronext: SAN and NYSE: SNY) and ...
|
|
Regeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement
Jun 11, 2009
|
47.6 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jun. 11, 2009--
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today
that it has entered into two royalty agreements with Novartis Pharma AG
that rep...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds